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Abstract 
Specific inhibitors of Cytochrome P4502C9 enzyme (CYP2C9) viz. clopidogrel, fenofibrate fluvoxamine and sertraline 
at concentration of 50, 100, 150 and 200 µM were employed to investigate the nature of enzyme involved in biocon-
version of meloxicam to its main metabolite 5-OH methyl meloxicam by Cunninghamella blakesleeana. Virtual screen-
ing for interaction of specific CYP2C9 inhibitors with human CYP2C9 enzyme was performed by molecular docking 
using Auto dock vina 4.2 version. The in silico studies were further substantiated by in vitro studies, which indicated 
fenofibrate to be a potent inhibitor of CYP2C9 enzyme followed by sertraline, clopidogrel and fluvoxamine, respec-
tively. Two-stage fermentation protocol was followed to study metabolism of meloxicam and its inhibition by different 
CYP2C9 inhibitors. Meloxicam metabolites were identified using HPLC, LC–MS analysis and based on previous reports, 
as 5-OH methyl meloxicam (M1), 5-carboxy meloxicam (M2) and an unidentified metabolite (M3). All the inhibitors 
tested in the study showed a clear concentration dependent inhibition of meloxicam metabolism. The results suggest 
that the enzymes involved in metabolism of meloxicam in C. blakesleeana are akin to mammalian metabolism. Hence, 
C. blakesleeana can be used as a model organism in studying drug interactions and also in predicting mammalian 
drug metabolism.
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Background
Drug–drug interaction is a condition where one drug 
affects the activity of the other by increasing or decreas-
ing its activity. These interactions are seen in patients 
suffering from chronic ailments such as congestive heart 
failure, rheumatic diseases, hypertension, cancer, and 
human immunodeficiency which require multiple drug 
therapy and may result in adverse drug interactions 
manifested as a loss in drug efficacy (Doucet et al. 2002). 
Co-administration of ketoconazole and terfenadine was 
reported to cause potentially life-threatening ventricu-
lar arrhythmias (Manahan et al. 1990) and an interaction 
between sorivudine and fluorouracil also resulted in fatal 
toxicity (Watabe 1996; Sokuda et al. 1997). Cytochrome 
enzymes play a major role in metabolizing drugs and 
the activity of this group of enzymes or a single CYP can 
determine patient’s response to drug therapy. Therefore, 
modulation of the activity of CYPs by a given drug is a 
critical issue for the assessing the safety and efficacy of 
a drug. Inhibition of CYP can increase systemic expo-
sure leading to severe toxic side effects of the drug or 
another concomitantly given medication that is metabo-
lized by the respective CYP(s) (Romet et al. 1994; Wandel 
et al. 1998). Cardiac toxicity caused by co-administering 
the antihistamine terfenadine with the antifungal keto-
conazole or the antibiotic erythromycin is an example 
whereby inhibition of CYP 3A4 results in elevated terfen-
adine levels, resulting in prolongation of the QTc inter-
val (Venkatakrishna et al. 2000). Similarly, the increased 
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bleeding in patients on warfarin therapy has been attrib-
uted to inhibition of its metabolism (Chan 1998).
Progress in CYP enzymology and biochemistry in 
the recent past suggests that, the drug interactions are 
based on enzyme inhibition. This aspect can be fur-
ther investigated using in  vitro techniques with micro-
somes, expressed enzymes, or cell systems (Pichard 
et  al. 1990; Von Moltke et  al. 1994). An understanding 
of the drug-metabolizing enzymes role in the clearance 
of compounds and of drug–drug interactions caused 
by co-administered medications is an essential compo-
nent of both the drug discovery process and its thera-
peutics. Currently variety of tools are available to assess 
the potential of a drug in inhibiting different P450 
enzymes invitro which include human liver tissue, cDNA 
expressed P450 enzymes, and specific probe substrates. 
Among them, human liver microsomal preparations 
are method of choice. The utility of tissues from indi-
vidual donors for inhibition of enzyme selective studies 
is limited by sufficiency of catalytic activity present in 
the tissue. Alternately, when a specific enzyme is to be 
investigated, recombinant P450s can be used. The most 
preferred test systems are microsomes and recombinant 
p450 enzymes as they are readily available than human 
hepatocytes and p450 kinetic measurements are not 
confounded with other metabolic processes or cellular 
uptake. A major disadvantage of microsomes or recombi-
nant enzymes is that they do not represent the true phys-
iological environment. (e.g., not all Phase II enzymes are 
present) if that is of interest to study. These processes are 
also associated with high cost.
Microorganisms and their enzymes have proved to be 
versatile biocatalysts and are involved in the transfor-
mation of complex organic materials to produce bioac-
tive compounds and some of them have the potential 
to metabolise or degrade the desired compounds. This 
process is simple, hazard free, minimizes the problems 
of racemization, isomerization, epimerization and rear-
rangement that generally occur during chemical process, 
renewable or recycled many times, economical and eco-
friendly. Most of the fungal cultures were employed in 
biotransformation of drugs especially the fungus belong-
ing to the genus Cunninghamella is well documented, 
also as a model of mammalian biotransformation (Zhang 
et  al. 2006; Lisowska et  al. 2006). The advantages of 
microbial systems as an in vitro model for drug biotrans-
formation include its low cost, ease of handling, scale up 
capacity and its potential to reduce the use of animals 
(Pupo et al. 2007). Further it is an efficient and environ-
mentally friendly process.
Meloxicam, the anti-inflammatory drug used for the 
treatment of rheumatic disease is mainly metabolized 
to 5-hydroxymethyl metabolite that is further converted 
to a 5-carboxy metabolite (Schmid et  al. 1995) and to 
other derivatives. The 5-hydroxylation of meloxicam is 
predominantly catalyzed by CYP2C9 and with a minor 
contribution of CYP3A4 (Chesne et al. 1998). Any medi-
cation inhibiting CYP2C9 can potentially block the con-
version of meloxicam into its metabolites. 5-OH methyl 
meloxicam was found to be the major metabolite in 
mammals and the microbes studied so far (Busch et  al. 
1998; Prasad et al. 2009a).
In our earlier studies, three major metabolites of 
meloxicam viz. 5-OH methyl meloxicam (M1), 5-carboxy 
meloxicam (M2) and an unidentified metabolite (M3) 
were recorded employing C. blakesleeana as a model 
organism (Prasad et  al. 1998). In the present investiga-
tion, we report the inhibition of the enzyme involved in 
the bioconversion of meloxicam to 5-OH methyl meloxi-
cam using specific CYP2C9 inhibitors viz. clopidogrel, 
fenofibrate, fluoxamine and sertraline in C. blakesleeana.
Results and discussion
In silico studies
The CYP2C9 (receptor) 3D structure with PDB I.D 1OG2 
was obtained from PDB data base and the ligands from 
PubChem and are converted to 3D PDB files. After pre-
paring receptor (CYP2C9) and 4 ligands (clopidogrel, 
fenofibrate, sertraline and fluvoxamine), each ligand 
individually was subjected to docking with human 
cytochrome P450 (CYP) 2C9 enzyme (receptor) and the 
docking was found to be successful based on the evident 
formation of complexes of CYP2C9 enzyme with specific 
human CYP2C9 enzyme inhibitors. The hydrogen bond 
interactions, binding energy, bond length, RMSD, active 
site residues and orientation of the docked compound 
within the active site were visualized using PyMOL soft-
ware. All the test compounds screened showed best fit 
RMSD value of 0.000, indicating statistically significant 
interaction. The binding energies were found to be, −7.8, 
−7.3, −6.9 and −6.2 kcal mol−1 for fenofibrate, sertraline, 
clopidogrel, and fluvoxamine, respectively (Table 1). The 
negative and low value of ΔG indicated a strong favorable 
bonding between CYP2C9 enzyme and the ligands, sug-
gesting that the bound ligand was in its most favorable 
conformations.
Fenofibrate showed binding energy of −7.8 which 
was found to be higher as compared to other inhibitors 
tested with one hydrogen bond interacting with CYP2C9 
enzyme in the complex at O-24 position of the ligand. 
The residue involved in this interaction was ASN-217. 
Sertraline was found to be potent inhibitor of CYP2C9 
next only to fenofibrate with binding energy of 7.3 kcal/
mol. Interestingly, sertraline could not form any hydro-
gen bonding with receptor (CYP2C9) indicating the 
interaction to be hydrophobic. The surrounding amino 
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acids Arg-433, Thr-301, Val-113 may be involved in form-
ing hydrophobic interactions with sertraline.
Clopidogrel showed binding energy of −6.9  kcal/mol, 
forming one hydrogen bond with the receptor and was 
less potent as compared to fenofibrate and sertraline. The 
residue involved in forming hydrogen bonding was iden-
tified as ARG-97. Further, clopidogrel was involved in 
forming hydrogen bonding with oxygen at position O-20.
Even though, fluvoxamine showed two hydrogen bonds 
with the receptor with a bonding energy of −6.2, which 
was least potent as compared to other inhibitors tested. 
GLN-214 and ASN-217 are the two aminoacid residues 
that are involved in forming hydrogen bonds. The oxygen 
(O-21) of the ligand was involved in the bonding.
The details of binding energies, number of hydrogen 
bonds formed and catalytic site residues involved in pro-
tein–ligand complex of CYP2C9 with different ligands 
are depicted in Table 1 and Fig. 1.
In vitro studies
In the present investigation, three metabolites of meloxi-
cam M1, M2 and M3 employing C. blakesleeana were 
identified as reported earlier (Prasad et  al. 2009a) evi-
denced from HPLC analysis of ethyl acetate extract of 
the test and control samples. The metabolite peaks were 
identified in HPLC analysis of test sample basing on simi-
larity in UV spectra using photodiode array detection. 
The chromatogram of culture control (fungus without 
drug) showed no metabolites peaks and substrate control 
(drug without fungus) showed the presence of meloxicam 
only. The retention time for the metabolites M1, M2 and 
M3 were observed to be 5.5, 4.4, 6.6  min, respectively; 
while the retention time of meloxicam was found to be 
at 12.4 min in HPLC analysis (Fig. 2). The UV spectra of 
meloxicam and its metabolites were found to be similar 
indicating the parent molecule and its biotransformed 
metabolites had similar UV absorption pattern (Fig.  3). 
This indicates that meloxicam has undergone minor 
structural changes while basic moiety remains intact. 
The metabolites were quantified based on area under the 
peak recorded in the HPLC analysis taking the drug and 
metabolites peak areas together as 100 %.
The structure elucidation of the metabolites was car-
ried out from the m/z values of the protonated molecu-
lar ion peaks obtained in LC–MS analysis (Fig. 4), HPLC 
retention times, chromatographic elution order and with 
earlier reports (Busch et al. 1998; Prasad et al. 2009a).The 
metabolic pathway of meloxicam in C. blakesleeana was 
shown in Fig. 5.
LC–MS analysis of test sample showed a molecu-
lar ion at m/z = 368 [M + H] +, an increase of 16 m/z 
units to meloxicam indicating addition of a single oxygen 
atom. This suggests that the compound might be 5-OH 
methyl meloxicam (M1). The metabolite M1 formation 
from meloxicam was reported to mediate by cytochrome 
P450 2C9 with minor contribution of CYP3A4 enzyme 
in mammals (Chesne et  al. 1998). This derivative of 
meloxicam was also reported in Cunninghamella elegans, 
horses (Aberg et al. 2009) and in C. blakesleeana NCIM 
687 (Prasad et al. 2009a).
Metabolite M2 showed a molecular ion at m/z =  382 
[M + H]+ an increase of 14 m/z units, indicating clearly 
further addition of an oxygen and removal of two hydro-
gen atoms from M1. This compound might be 5-carboxy 
meloxicam (M2). The production of metabolite M1 using 
C. elegans NCIM 690, Saccharomyces cerevisiae NCIM 
3090, Bacillus subtilis MTCC 441, Pseudomonas putida 
NCIM 2783 and the production of both metabolites M1 
and M2 using Aspergillus niger NCIM 589, A. ochraceous 
NCIM 1140, C.echinulata NCIM 691 was reported ear-
lier (Prasad et al. 2009a, b) and by Aberg et al. (2009) in 
C. elegans and horses. These metabolites viz. M1, M2 
were also detected in mammals showing similar metabo-
lism of meloxicam (Busch et al. 1998; Aberg et al. 2009). 
The metabolites of meloxicam both M1 and M2 were 
reported to be pharmacologically inactive (Davies and 
Skjodt 1999).
A third metabolite with m/z 438 [M  +  H]  +  was 
recorded with 86  m/z units higher to meloxicam. 
The production of M3 using C. blakesleeana was also 
recorded by Prasad et  al. (2009b). This is an unidenti-
fied metabolite of meloxicam (M3). A probable molecu-
lar structure of metabolite M3 was presented in Fig.  3. 
However, further investigations are needed to confirm its 
Table 1 Ligands docked to crystal structure of human cytochrome P450 CYP2C9 (PDB: Code 10G2)
Ligand name Binding energy  
(kcal/mol)
Number of hydrogen  
bonds




Clopidogrel −6.9 1 2.6 ARG-97/2HH1 O-20
Fenofibrate −7.8 1 2.4 ASN-217/1HD2 O-24
Fluvoxamine −6.2 2 2.5
2.4
GLN-214/1HE2 ASN-217/1HD2 O-21
Sertraline −7.3 Hydrophobic interactions – – –
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Fig. 1 Virtual screening for interaction of specific CYP29 inhibitors (a–d) clopidogrel, Fenofibrate, fluvoxamine, sertraline with human CYP2C9 (PDB 
code: 1OG2) enzyme by molecular docking
Fig. 2 HPLC chromatogram showing metabolites of meloxicam in culture broth of C. blakesleeana
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structure. The LC–MS data, of the metabolites are pre-
sented in Table 2.
To find the nature of enzyme involved in M1 produc-
tion by C. blakesleeana, Specific inhibitors of CYP2C9 
were used in the study and successful inhibitory action of 
tested inhibitors was observed.
Inhibition of 5-OH methyl meloxicam (M1) formation 
from meloxicam was studied at 50, 100, 150 and 200 µM 
inhibitor concentrations using known human CYP2C9 
specific inhibitors viz. clopidogrel, fenofibrate, fluvox-
amine and sertraline. Fungal culture with meloxicam 
without inhibitor was used as control to know the actual 
percent production of M1; The experimental results are 
presented in Table 3.
From Table  3 it is clear that the yield of metabolite 
M1 was 75 % without addition of any inhibitors, while 
all the inhibitors employed in the present investigation 
Fig. 3 UV spectra of meloxicam and its metabolites produced by 
C. blakesleeana NCIM 687 using Photodiode array detector (PDA) of 
HPLC
Fig. 4 LC-MS spectra of metabolites detected in meloxicam fed culture broth of C. blakesleeana
Fig. 5 Metabolic pathway of meloxicam in C. blakesleeana NCIM 687
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indicated a clear concentration dependent inhibition 
of M1 formation from meloxicam, compared to the 
control.
At a concentration of 50,100 and 150  µM fenofibrate, 
sertraline and fluvoxamine showed similar  % inhibition 
of M1, while at 200 µM concentration, fenofibrate, sertra-
line and fluvoxamine resulted in 7.89, 11.23 and 22.53 % 
inhibition of M1, respectively. Among all the inhibi-
tors tested, clopidogrel was found to achieve maximum 
inhibition of M1 formation at 100 and 150 µM concen-
trations, which may be attributed to the saturation of 
binding sites.
Biomass production in control and test samples of fun-
gal cultures showed similar pattern of growth. There was 
no statistically significant difference (P  <  0.05) between 
fungal growth in controls and experimental groups, 
wherein the added test molecules had not impacted the 
growth of the fungus (Table 3).
Fenofibrate at 50–200  µM and clopidogrel at 
50–150  µM were found to be the potent inhibitors of 
M1 formation followed by sertraline and fluoxamine at 
50–200 µM. Similar results with clopidogrel and fenofi-
brate was reported in human liver microsomes by Rich-
ter et al. (2004) and Vecera et al. (2011). Schmider et al. 
(1997) also reported inhibition of CYP2C9 using ser-
traline in human liver microsomes. Strong inhibition of 
CYP2C9 with fluvoxamine in human liver microsomes 
was also recorded by Hemeryck et al. (1999) and Madsen 
et al. (2011). Zing et al. (2010) also studied the influence 
of fluvoxamine on CYP2C9*3 and CYP2C9*13 enzymes 
by expressing in yeast cells.
In the present study, in silico analysis, was further 
substantiated by in  vitro experimental data suggesting 
the inhibitory action of tested CYP2C9 inhibitors on 
CYP2C9 enzyme. Among inhibitors tested fenofibrate 
was found to be a potent inhibitor of M1 formation 
Table 2 LC–MS data of meloxicam metabolites by C. blakesleeana NCIM 687
Metabolite Rt [M + H]+ Predicted molecular formula Predicted reaction
Meloxicam 12.4 352 C14H13N3O4S2 –
5-OH methyl meloxicam (Ml) 5.5 368 C14H13N3O5S2 Hydroxylation
5-Carboxy meloxicam (M2) 4.4 382 C14H11N3O6S2 Carboxylation
Unidentified metabolite (M3) 6.6 438 – –
Table 3 Effect of different CYP2C9 inhibitors on meloxicam metabolism by C. blakesleeana
The values are based on three independent experiments; values are Mean ± standard deviation
* P < 0.01;  #  P < 0.05-non significant




 Clopidogrel (μM) 50 33.55 ± 0.74* 11.52 ± 0.02
100 23.22 ± 0.24* 11.56 ± 0.03
150 14.59 ± 0.91* 11.42 ± 0.02
200 13.03 ± 1.96* 10.33 ± 0.02
 Fenofibrate (μM) 50 39.13 ± 0.78* 11.62 ± 0.26
100 36.45 ± 0.64* 11.52 ± 0.03
150 25.36 ± 0.14* 11.54 ± 0.03
200 7.89 ± 0.12* 11.51 ± 0.03
 Fluvoxamine (μM) 50 35.48 ± 1.20* 11.74 ± 0.02
100 33.89 ± 0.24* 11.61 ± 0.03
150 27.91 ± 1.03* 11.57 ± 0.04
200 22.53 ± 0.66* 10.31 ± 0.02
 Sertraline (μM) 50 40.77 ± 0.50* 11.53 ± 0.005
100 35.73 ± 0.95* 11.51 ± 0.02
150 26.96 ± 0.72* 11.71 ± 0.02
200 11.23 ± 0.44* 10.61 ± 0.03
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followed by sertralinee, fluoxamine and clopidogrel. 
Additionally, it is clear that CYP2C9 like enzyme exists in 
C. blakesleeana and had catalyzed the formation of 5-OH 
methyl meloxicam (M1) from meloxicam which, is akin 
to mammalian xenobiotics.
Conclusion
In the present investigation, in silico studies clearly pre-
dicted the interaction of specific CYP2C9 inhibitors with 
human CYP2C9 enzyme. The drug docking studies were 
substantiated by in vitro studies. The metabolite M1 for-
mation from meloxicam by C. blakesleeana was strongly 
inhibited using specific inhibitors of CYP2C9 viz. fenofi-
brate followed by sertralinee, clopidogrel and fluvox-
amine. Similarly, metabolites of meloxicam reported in 
mammals were also detected employing C. blakesleeana 
as a model organism. This is indicative of the existence of 
a similar type of enzyme system present in fungus that is 
akin to mammals. Hence, C. blakesleeana may be used as 
a model organism in predicting drug–drug interactions as 
well as in studying mammalian drug metabolism, which 
provides true physiological environment as in animals.
Methods
Chemicals
Meloxicam was gifted by Unichem Laboratories Mumbai, 
India. Clopidogrel, fenofibrate fluvoxamine and sertraline 
were obtained from the Dr. Reddy Labs, Hyderabad, KU 
Warangal. Methanol was of HPLC grade obtained from 
Ranbaxy Laboratories Ltd., New Delhi, India. Peptone, 
yeast extract, NaCl, glucose, K2HPO4 and all other chem-
icals were obtained from Himedia Labs, Mumbai, India.
Microorganism
Cunninghamella blakesleeana NCIM 687 was procured 
from National Chemical Laboratory, Pune, India. Stock 
cultures were maintained on Potato dextrose agar slants 
at 4 °C and sub cultured for every 3 months for maintain-
ing viability.
In silico studies: Virtual screening for interaction 
of specific CYP29 inhibitors with human CYP2C9 enzyme 
by molecular docking
In the present In silico study, specific human CYP2C9 
enzyme inhibitors viz. clopidogrel, fenofibrate fluvoxam-
ine and sertraline were used as ligands and were screened 
against the crystal structure of human cytochrome P450 
CYP2C9 enzyme with PDB code 1OG2. An advanced 
molecular docking program Auto Dock Vina, version 
4.2 available from http://vina.scripps.edu/ was applied 
to select ligand active against CYP2C9 enzyme and esti-
mating the binding affinities (kcal  mol−1). The CYP2C9 
enzyme was downloaded from protein data bank (PDB 
code: 1OG2) and all the ligands were downloaded from 
PubChem database and optimised by removing water 
molecules and adding hydrogens. Later, both ligands 
and receptor was saved as pdbqt format. A grid box 
was adjusted to have center x = 14.846, y = 69.693, and 
z  =  21.831 to cover the pocket with the main residues 
of enzyme binding site. The best conformation was cho-
sen with the lowest docked energy, based on complete 
docking search (ten runs). The interactions of CYP2C9 
enzyme with the ligands, hydrogen bonds, bond lengths, 
Root Mean Square Difference (RMSD) were analyzed 
using PyMOL software.
In vitro studies: fermentation conditions
Microbial fermentation was carried out in a liquid broth 
containing (per liter) Yeast extract (5  g), glucose(20  g), 
peptone (5 g), NaCl (5 g), K2HPO4 (5 g). Specified quan-
tities of the media ingredients were dissolved in distilled 
water, pH was adjusted to 6.0 with either 0.1  N HCl or 
0.1  N NaOH and sterilized by autoclaving and cooled 
before inoculation. Transformation of meloxicam was 
performed by incubating culture flasks on a rotary shaker 
at 120 rpm and 27 °C according to two stage fermentation 
procedure. In the first stage, fermentation was initiated by 
inoculating a 100 ml culture flask consisting of 20 ml of 
liquid broth with loopful of spores obtained from freshly 
grown agar slant. After incubation for 48 h second stage 
cultures were initiated in the same medium using inoc-
ulum of 1.0  ml from the first stage culture per 20  ml of 
medium in a 100-ml culture flask and incubated for 24 h 
under similar conditions. Two mg of meloxicam (in 200 µl 
DMSO) was added to the culture flasks and incubated 
further for another 4 days.
Two types of controls were run simultaneously with the 
fermentation and worked up with the same method. One 
was culture control consisted of a fermentation blank 
in which the microorganism was grown under identical 
conditions without the substrate. The other was substrate 
control comprised of meloxicam added to the sterile 
medium without fungus and incubated under similar 
conditions. Three independent experiments were carried 
out.
Extraction of metabolites
At the end of incubation period, the fungal mat was 
separated from the culture broth and dried, pH of the 
broth was acidified to 3.0 with orthophosphoric acid 
and the later was extracted with three volumes of ethyl 
acetate, the combined organic extracts were evaporated 
using a rotary vacuum evaporator and dried over a bed 
of sodium sulfate. The resultant residues were analyzed 
by HPLC and LC–MS for presence and identification of 
metabolites.
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Analytical procedures
HPLC analysis was performed according to the method 
described by Prasad et  al. (2009a). The samples were 
analyzed using an Agilent 1260 infinity system (USA) 
by injecting 20 µl into the syringe-loading sample injec-
tor (Agilent, Model G1328C). The column used was Agi-
lent, Zorbax Eclipse XDB-C18, 4.6 × 250 mm and 5 µm 
(USA). A mixture of methanol–water (pH adjusted to 
3.0 with orthophosphoric acid) in the ratio of 60:40 was 
the mobile phase used. The analysis was performed at a 
flow rate of 1 ml/min isocratically and the analytes were 
detected at 363  nm using a photodiode array detec-
tor (Agilent, Model G1315D, USA). LC–MS analysis 
was carried out using system MDS SCIEX API-4000,Q-
TRAP, Canada with MS/MS API-4000,Q-Trap detector 
with triple quadrapole mass detector. Chromatographic 
separation was achieved by Waters column X Terra C18, 
250 × 4.6 mm, 5 µm and the same mobile phase used for 
HPLC was used (pH adjusted to 3.0 with formic acid). 
The ESI detection was set to positive mode. A tempera-
ture of 300 °C and scan range of 50–900 was set for the 
analysis. The transformed compounds were identified 
from the masses of products obtained in LC–MS analysis 
and previous reports.
Metabolic inhibition of meloxicam
The inhibition of metabolism of meloxicam was studied 
using specific inhibitors of human CYP2C9 viz. clopi-
dogrel, fenofibrate, fluoxamine and sertraline in fungal 
culture C. blakesleeana NCIM 687. The fungal culture 
was grown in the same medium which is used for bio-
transformation, and a two-stage fermentation protocol 
was adapted for the study. Each 20  ml of the second-
stage cultures was added with 50, 100, 150, and 200  µg 
of inhibitors (dissolved in 100 μl DMSO) separately and 
incubated at 27 °C for 24 h. The CYP2C9 enzyme inhib-
ited second-stage cultures were added with 2 mg each of 
meloxicam dissolved in 200 μl DMSO. Each inhibitor was 
studied in triplicates while running suitable controls. The 
contents of the flasks were extracted and analyzed using 
the procedure similar to that employed for meloxicam 
metabolism by C. blakesleeana. The percent of 5′-OH 
methyl meloxicam production in the cultures was calcu-
lated for studying the metabolic inhibition by inhibitors 
used.
Statistical analysis
The experimental results were analyzed statistically (stu-
dent’s t test) using Sigma Stat statistical software, version 
11.0 (Jandel Corporation, Sam Rafael, CA, USA) software 
program package. The P values below 0.01 were consid-
ered statistically significant. The results were expressed 
as mean  ±  SD. The experiments were carried out in 
triplicates.
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